{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T04:07:49Z","timestamp":1773979669075,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC 113-2314-B-016-007"],"award-info":[{"award-number":["NSTC 113-2314-B-016-007"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Otorhinolaryngol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00405-025-09975-9","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T21:11:51Z","timestamp":1768943511000},"page":"1771-1785","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic targeting of the FSP1-ACSL4 axis reverses cisplatin resistance via ferroptosis induction in drug-tolerant papillary thyroid carcinoma"],"prefix":"10.1007","volume":"283","author":[{"given":"Chien-Yi","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Ming","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Yasir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Chen","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijesh Kumar","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9730-1798","authenticated-orcid":false,"given":"Shao-Cheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"issue":"28","key":"9975_CR1","first-page":"17","volume":"1","author":"P Manjusha","year":"2018","unstructured":"Manjusha P, Kandathil JP, Nayanar SK, Jones J, Sajith B (2018) Clinicopathological spectrum of anaplastic carcinoma of thyroid\u20145 year experience from a tertiary cancer centre. Gulf J Oncol 1(28):17\u201322","journal-title":"Gulf J Oncol"},{"issue":"3","key":"9975_CR2","doi-asserted-by":"publisher","first-page":"E552","DOI":"10.3390\/cancers12030552","volume":"12","author":"N Onoda","year":"2020","unstructured":"Onoda N, Sugitani I, Ito KI, Suzuki A, Higashiyama T, Fukumori T et al (2020) Evaluation of the 8th edition TNM classification for anaplastic thyroid carcinoma. Cancers (Basel) 12(3):E552","journal-title":"Cancers (Basel)"},{"key":"9975_CR3","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","volume":"740","author":"S Dasari","year":"2014","unstructured":"Dasari S, Tchounwou PB (2014) Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol 740:364\u2013378","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"9975_CR4","doi-asserted-by":"publisher","first-page":"219","DOI":"10.34172\/joddd.2021.036","volume":"15","author":"L Paya","year":"2021","unstructured":"Paya L et al (2021) Drug resistance against 5-fluorouracil and cisplatin in the treatment of head and neck squamous cell carcinoma: A systematic review. J Dent Res Dent Clin Dent Prospects 15(3):219\u2013225","journal-title":"J Dent Res Dent Clin Dent Prospects"},{"key":"9975_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2020.100773","volume":"13","author":"D Ribatti","year":"2020","unstructured":"Ribatti D, Tamma R, Annese T (2020) Epithelial\u2013mesenchymal transition in cancer: a historical overview. Transl Oncol 13:100773","journal-title":"Transl Oncol"},{"issue":"1","key":"9975_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03260-7","volume":"20","author":"X Chen","year":"2022","unstructured":"Chen X, Lin S, Lin Y, Wu S, Zhuo M, Zhang A et al (2022) BRAF-activated WT1 contributes to cancer growth and regulates autophagy and apoptosis in papillary thyroid carcinoma. J Transl Med 20(1):79. https:\/\/doi.org\/10.1186\/s12967-022-03260-7","journal-title":"J Transl Med"},{"key":"9975_CR7","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1016\/j.jtho.2021.07.017","volume":"16","author":"M Mikubo","year":"2021","unstructured":"Mikubo M, Inoue Y, Liu G, Tsao MS (2021) Mechanism of drug tolerant persister cancer cells: the landscape and clinical implication for therapy. J Thorac Oncol 16:1798\u20131809","journal-title":"J Thorac Oncol"},{"key":"9975_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-00313-5","volume":"5","author":"S Qin","year":"2020","unstructured":"Qin S, Jiang J, Lu Y, Nice EC, Huang C, Zhang J et al (2020) Emerging role of tumor cell plasticity in modifying therapeutic response. Signal Transduct Target Ther 5:228","journal-title":"Signal Transduct Target Ther"},{"key":"9975_CR9","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1111\/jcmm.13008","volume":"21","author":"H Yu","year":"2017","unstructured":"Yu H, Guo P, Xie X, Wang Y, Chen G (2017) Ferroptosis, a new form of cell death, and its relationships with tumourous diseases. J Cell Mol Med 21:648\u2013657","journal-title":"J Cell Mol Med"},{"key":"9975_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00239","volume":"11","author":"C Han","year":"2020","unstructured":"Han C, Liu Y, Dai R, Ismail N, Su W, Li B (2020) Ferroptosis and its potential role in human diseases. Front Pharmacol 11:239","journal-title":"Front Pharmacol"},{"key":"9975_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/ph11040137","volume":"11","author":"N Sukhbaatar","year":"2018","unstructured":"Sukhbaatar N, Weichhart T (2018) Iron regulation: macrophages in control. Pharmaceuticals (Basel) 11:137","journal-title":"Pharmaceuticals (Basel)"},{"key":"9975_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.freeradbiomed.2017.07.010","volume":"112","author":"G Cozza","year":"2017","unstructured":"Cozza G, Rossetto M, Bosello-Travain V, Maiorino M, Roveri A, Toppo S et al (2017) Glutathione peroxidase 4-catalyzed reduction of lipid hydroperoxides in membranes: the Polar head of membrane phospholipids binds the enzyme and addresses the fatty acid hydroperoxide group toward the redox center. Free Radic Biol Med 112:1\u201311","journal-title":"Free Radic Biol Med"},{"key":"9975_CR13","first-page":"5508","volume":"11","author":"L Luo","year":"2021","unstructured":"Luo L, Wang H, Tian W, Zeng J, Huang Y, Luo H (2021) Targeting ferroptosis for cancer therapy: iron metabolism and anticancer immunity. Am J Cancer Res 11:5508\u20135525","journal-title":"Am J Cancer Res"},{"key":"9975_CR14","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/j.bbrc.2020.01.066","volume":"523","author":"E Dai","year":"2020","unstructured":"Dai E, Zhang W, Cong D, Kang R, Wang J, Tang D (2020) Aifm2 blocks ferroptosis independent of ubiquinol metabolism. Biochem Biophys Res Commun 523:966\u2013971","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"9975_CR15","doi-asserted-by":"publisher","first-page":"5933","DOI":"10.1038\/s41467-023-41626-7","volume":"14","author":"Y Lv","year":"2023","unstructured":"Lv Y, Liang C, Sun Q, Zhu J, Xu H, Li X et al (2023) Structural insights into FSP1 catalysis and ferroptosis Inhibition. Nat Commun 14(1):5933","journal-title":"Nat Commun"},{"issue":"1","key":"9975_CR16","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nchembio.2239","volume":"13","author":"M Conrad","year":"2017","unstructured":"Conrad M et al (2017) ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol 13(1):91\u201398","journal-title":"Nat Chem Biol"},{"issue":"3","key":"9975_CR17","doi-asserted-by":"publisher","first-page":"165","DOI":"10.14348\/molcells.2023.0005","volume":"46","author":"E Chapman","year":"2023","unstructured":"Chapman E, Zhang DD et al (2023) Anti-ferroptotic effects of Nrf2: beyond the antioxidant response. Molecules Cells 46(3):165\u2013175","journal-title":"Molecules Cells"},{"key":"9975_CR18","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.semcancer.2020.11.013","volume":"79","author":"P Fallahi","year":"2022","unstructured":"Fallahi P, Ferrari SM, Galdiero MR, Varricchi G, Elia G, Ragusa F et al (2022) Molecular targets of tyrosine kinase inhibitors in thyroid cancer. Semin Cancer Biol 79:180\u2013196","journal-title":"Semin Cancer Biol"},{"issue":"10370","key":"9975_CR19","first-page":"635","volume":"401","author":"ME Cabanillas","year":"2023","unstructured":"Cabanillas ME, McFadden DG, Durante C (2023) Thyroid cancer. Lancet 401(10370):635\u2013650","journal-title":"Lancet"},{"issue":"3","key":"9975_CR20","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41574-020-00448-z","volume":"17","author":"M Schlumberger","year":"2021","unstructured":"Schlumberger M, Leboulleux S (2021) Current practice in patients with differentiated thyroid cancer. Nat Rev Endocrinol 17(3):176\u2013188","journal-title":"Nat Rev Endocrinol"},{"issue":"11","key":"9975_CR21","first-page":"1397","volume":"30","author":"Y Zhang","year":"2023","unstructured":"Zhang Y et al (2023) Identification of structurally diverse FSP1 inhibitors that sensitize cancer cells to ferroptosis. Cell Chem Biol 30(11):1397\u20131412","journal-title":"Cell Chem Biol"},{"issue":"7","key":"9975_CR22","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41568-022-00459-0","volume":"22","author":"G Lei","year":"2022","unstructured":"Lei G, Zhuang L, Gan B (2022) Targeting ferroptosis as a vulnerability in cancer. Nat Rev Cancer 22(7):381\u2013396","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"9975_CR23","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1080\/15548627.2020.1810918","volume":"17","author":"X Chen","year":"2021","unstructured":"Chen X, Li J, Kang R, Klionsky DJ, Tang D (2021) Ferroptosis: machinery and regulation. Autophagy 17(9):2054\u20132081","journal-title":"Autophagy"},{"issue":"4","key":"9975_CR24","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","volume":"22","author":"X Jiang","year":"2021","unstructured":"Jiang X, Stockwell BR, Conrad M (2021) Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol 22(4):266\u2013282","journal-title":"Nat Rev Mol Cell Biol"},{"key":"9975_CR25","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41586-019-1707-0","volume":"575","author":"S Doll","year":"2019","unstructured":"Doll S et al (2019) FSP1 is a glutathione-independent ferroptosis suppressor. Nature 575:693\u2013698","journal-title":"Nature"},{"issue":"35","key":"9975_CR26","first-page":"e2305632120","volume":"120","author":"K Hu","year":"2023","unstructured":"Hu K et al (2023) FSP1 confers ferroptosis resistance in KEAP1-mutant non-small-cell lung cancer. PNAS 120(35):e2305632120","journal-title":"PNAS"},{"issue":"7784","key":"9975_CR27","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41586-019-1707-0","volume":"575","author":"S Doll","year":"2019","unstructured":"Doll S, Freitas FP, Shah R, Aldrovandi M, da Silva MC, Ingold I et al (2019) FSP1 is a glutathione-independent ferroptosis suppressor. Nature 575(7784):693\u20138","journal-title":"Nature"},{"issue":"1","key":"9975_CR28","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1038\/s41467-022-29905-1","volume":"13","author":"P Koppula","year":"2022","unstructured":"Koppula P, Lei G, Zhang Y, Yan Y, Mao C, Kondiparthi L et al (2022) A targetable CoQ-FSP1 axis drives ferroptosis- and radiation-resistance in KEAP1 inactive lung cancers. Nat Commun 13(1):2206","journal-title":"Nat Commun"},{"issue":"4","key":"9975_CR29","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1007\/s10637-021-01070-0","volume":"39","author":"MR Liu","year":"2021","unstructured":"Liu MR, Zhu WT, Pei DS (2021) System Xc\u2013: a key regulatory target of ferroptosis in cancer. Invest New Drugs 39(4):1123\u20131131","journal-title":"Invest New Drugs"},{"issue":"4","key":"9975_CR30","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.chembiol.2020.03.013","volume":"27","author":"BR Stockwell","year":"2020","unstructured":"Stockwell BR, Jiang X (2020) The chemistry and biology of ferroptosis. Cell Chem Biol 27(4):365\u2013375","journal-title":"Cell Chem Biol"},{"issue":"9","key":"9975_CR31","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.202105043","volume":"220","author":"B Gan","year":"2021","unstructured":"Gan B (2021) Mitochondrial regulation of ferroptosis. J Cell Biol 220(9):e202105043","journal-title":"J Cell Biol"},{"issue":"1","key":"9975_CR32","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41392-024-01769-5","volume":"9","author":"Q Zhou","year":"2024","unstructured":"Zhou Q, Meng Y, Li D, Yao L, Le J, Liu Y et al (2024) Ferroptosis in cancer: from molecular mechanisms to therapeutic strategies. Signal Transduct Target Ther 9(1):55","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"9975_CR33","first-page":"2127","volume":"28","author":"D Tang","year":"2021","unstructured":"Tang D, Chen X, Kang R, Kroemer G (2021) Ferroptosis: molecular mechanisms and health implications. Cell Death Differ 28(7):2127\u20132139","journal-title":"Cell Death Differ"},{"issue":"2","key":"9975_CR34","first-page":"121","volume":"31","author":"B Hassannia","year":"2021","unstructured":"Hassannia B, Vandenabeele P, Vanden Berghe T (2021) Targeting ferroptosis to iron out cancer. Trends Cell Biol 31(2):121\u2013134","journal-title":"Trends Cell Biol"},{"issue":"2","key":"9975_CR35","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41422-020-00441-1","volume":"31","author":"D Tang","year":"2021","unstructured":"Tang D, Chen X, Kang R, Kroemer G (2021) Ferroptosis: molecular mechanisms and health implications. Cell Res 31(2):107\u2013125","journal-title":"Cell Res"},{"issue":"6","key":"9975_CR36","first-page":"601","volume":"1","author":"S Shen","year":"2020","unstructured":"Shen S, Vagner S, Robert C (2020) Persistent cancer cells: the deadly survivors. Nat Cancer 1(6):601\u2013613","journal-title":"Nat Cancer"},{"issue":"51","key":"9975_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201904197","volume":"31","author":"C Liang","year":"2019","unstructured":"Liang C, Zhang X, Yang M, Dong X (2019) Recent progress in ferroptosis inducers for cancer therapy. Adv Mater 31(51):e1904197","journal-title":"Adv Mater"},{"issue":"1","key":"9975_CR38","first-page":"1","volume":"4","author":"P Wang","year":"2023","unstructured":"Wang P, Ke B, Ma G (2023) Drug-tolerant persister cancer cells. J Natl Cancer Cent 4(1):1\u20135","journal-title":"J Natl Cancer Cent"},{"issue":"1","key":"9975_CR39","first-page":"627","volume":"16","author":"YC Wu","year":"2024","unstructured":"Wu YC, Huang CS, Hsieh MS, Huang CM, Setiawan SA, Yeh CT et al (2024) Targeting of FSP1 regulates iron homeostasis in drug-tolerant persister head and neck cancer cells via lipid-metabolism-driven ferroptosis. Aging 16(1):627\u2013647","journal-title":"Aging"},{"key":"9975_CR40","doi-asserted-by":"publisher","first-page":"892957","DOI":"10.3389\/fmolb.2022.892957","volume":"9","author":"C Qu","year":"2022","unstructured":"Qu C, Peng Y, Liu S (2022) Ferroptosis biology and implication in cancers. Front Mol Biosci 9:892957","journal-title":"Front Mol Biosci"},{"issue":"15","key":"9975_CR41","doi-asserted-by":"crossref","first-page":"6810","DOI":"10.7150\/thno.77243","volume":"12","author":"X Zhang","year":"2022","unstructured":"Zhang X, Yu K, Ma L, Qian Z (2022) Therapeutic targeting of ferroptosis in cancer treatment: a review. Theranostics 12(15):6810\u20136825","journal-title":"Theranostics"},{"issue":"4","key":"9975_CR42","first-page":"100","volume":"51","author":"J Zeng","year":"2024","unstructured":"Zeng J et al (2024) Inhibition of FSP1: A new strategy for the treatment of tumors (Review). Oncol Rep 51(4):100\u2013112","journal-title":"Oncol Rep"},{"key":"9975_CR43","doi-asserted-by":"publisher","first-page":"1499125","DOI":"10.3389\/fonc.2024.1499125","volume":"14","author":"H Sun","year":"2024","unstructured":"Sun H et al (2024) Targeting ferroptosis: a promising strategy to overcome drug resistance. Front Oncol 14:1499125","journal-title":"Front Oncol"},{"key":"9975_CR44","first-page":"680401","volume":"11","author":"Z Wang","year":"2021","unstructured":"Wang Z, Ding Y, Wang X, Lu S (2021) Ferroptosis in anticancer therapy: regulatory mechanisms and applications. Front Oncol 11:680401","journal-title":"Front Oncol"},{"key":"9975_CR45","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/ame2.12077","volume":"2","author":"LM Granat","year":"2019","unstructured":"Granat LM, Kambhampati O, Klosek S, Niedzwecki B, Parsa K, Zhang D (2019) The promises and challenges of patient-derived tumor organoids in drug development and precision oncology. Anim Model Exp Med 2:150\u2013161","journal-title":"Anim Model Exp Med"},{"key":"9975_CR46","doi-asserted-by":"publisher","unstructured":"Vivarelli S, Candido S, Caruso G, Falzone L, Libra M (2020) Patient-derived tumor organoids for drug repositioning in cancer care: a promising approach in the era of tailored treatment. Cancers (Basel) 12(12):3636. https:\/\/doi.org\/10.3390\/cancers12123636","DOI":"10.3390\/cancers12123636"}],"container-title":["European Archives of Oto-Rhino-Laryngology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-025-09975-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00405-025-09975-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-025-09975-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T03:02:42Z","timestamp":1773975762000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00405-025-09975-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["9975"],"URL":"https:\/\/doi.org\/10.1007\/s00405-025-09975-9","relation":{},"ISSN":["0937-4477","1434-4726"],"issn-type":[{"value":"0937-4477","type":"print"},{"value":"1434-4726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]},"assertion":[{"value":"28 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The research protocol (TSGH IRB No. B202205171) was reviewed and approved by the Institutional Review Board of the Tri-Service General Hospital, Taipei, Taiwan. All methods were performed in accordance with the relevant guidelines and regulations. All patients provided written informed consents prior to participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.The authors declare the following financial interests\/personal relationships which may be considered as potential competing interests:Shao-Cheng Liu reports financial support was provided by National Defense Medical Center. Reports a relationship with that includes:. Has patent pending to. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}]}}